Ecopetrol
EC
Apple
AAPL
D.R. Horton
DHI
Meritage Homes
MTH
Lennar Corp
LEN
US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.1223
- +0.0013+1.07%
Close Mar 31 16:00 ET
- 0.1261
- +0.0038+3.11%
Post 20:01 ET
8.84MMarket Cap-0.39P/E (TTM)
0.1347High0.1200Low305.76KVolume0.1200Open0.1210Pre Close38.62KTurnover0.49%Turnover RatioLossP/E (Static)72.29MShares0.620052wk High-6.79P/B7.62MFloat Cap0.110552wk Low--Dividend TTM62.31MShs Float836.0000Historical High--Div YieldTTM12.15%Amplitude0.1105Historical Low0.1260Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
AIM ImmunoTech Stock Forum
https://www.moomoo.com/t/news/flash/20043806/zzrMYvU3zb
called it he knows more than we know so let it run baby we holding with you
don't be fooled into over paying eyes on the spread
not a bad average if I say so myself
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Wednesday, 26th February at 1:20 pm
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AIM) ("AIM" or the "Company") today announced that it received notice from the NYSE American (the "American") that the American has accepted the Company's Plan to regain compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) o...
👀
extracted from X, NFA
Our lead program is an immuno-modulator that has shown positive data published in
numerous well-respected journals and forums. Learn more: bit.ly/4gzyqnz
No comment yet